6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
described	VBN	described	described	describ	N	O
in	IN	in	in	in	N	O
more	JJR	more	more	more	N	O
detail	NN	detail	detail	detail	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
section	NN	section	section	section	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
label	NN	label	label	label	N	O
:	:	:	:	:	N	O

Somnolence	NNP	somnolence	somnolence	somnol	Y	B-AdverseReaction
sedation	NN	sedation	sedation	sedat	Y	B-AdverseReaction
and	CC	and	and	and	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O

RLS	NN	rls	rls	rl	N	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
2	CD	2	2	2	N	O
times	NNS	times	time	time	N	O
the	DT	the	the	the	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
somnolence	JJ	somnolence	somnolence	somnol	Y	B-AdverseReaction
sedation	NN	sedation	sedation	sedat	Y	B-AdverseReaction
and	CC	and	and	and	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

PHN	NN	phn	phn	phn	N	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
and	CC	and	and	and	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
dizziness	JJ	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
XenoPort	NN	xenoport	xenoport	xenoport	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
877	CD	877	877	877	N	O
-	:	-	-	-	N	O
XENOPRT	NN	xenoprt	xenoprt	xenoprt	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
877	CD	877	877	877	N	O
-	:	-	-	-	N	O
936	CD	936	936	936	N	O
-	:	-	-	-	N	O
6778	CD	6778	6778	6778	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
all	DT	all	all	all	N	O
controlled	VBN	controlled	controlled	control	N	O
and	CC	and	and	and	N	O
uncontrolled	JJ	uncontrolled	uncontrolled	uncontrol	N	O
trials	NNS	trials	trial	trial	N	O
across	IN	across	across	across	N	O
various	JJ	various	various	variou	N	O
patient	NN	patient	patient	patient	N	O
populations	NNS	populations	population	popul	N	O
,	,	,	,	,	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
300	CD	300	300	300	N	O
patients	NNS	patients	patient	patient	N	O
have	VBP	have	have	have	N	O
received	VBN	received	received	receiv	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
orally	RB	orally	orally	oral	N	O
in	IN	in	in	in	N	O
daily	JJ	daily	daily	daili	N	O
doses	NNS	doses	dos	dose	N	O
ranging	VBG	ranging	ranging	rang	N	O
from	IN	from	from	from	N	O
600	CD	600	600	600	N	O
to	TO	to	to	to	N	O
3	CD	3	3	3	N	O
,	,	,	,	,	N	O
600	CD	600	600	600	N	O
mg	NN	mg	mg	mg	N	O
.	.	.	.	.	N	O

Restless	NNP	restless	restless	restless	Y	O
Legs	NNP	legs	leg	leg	N	O
Syndrome	NNP	syndrome	syndrome	syndrom	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
in	IN	in	in	in	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
201	CD	201	201	201	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
RLS	NNP	rls	rls	rl	N	O
included	VBD	included	included	includ	N	O
613	CD	613	613	613	N	O
exposed	VBN	exposed	exposed	expos	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
and	CC	and	and	and	N	O
371	CD	371	371	371	N	O
exposed	VBN	exposed	exposed	expos	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1	CD	1	1	1	N	O
year	NN	year	year	year	N	O
.	.	.	.	.	N	O

HORIZANT	NNP	horizant	horizant	horiz	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
RLS	NNP	rls	rls	rl	N	O
was	VBD	was	wa	wa	N	O
studied	VBN	studied	studied	studi	N	O
primarily	RB	primarily	primarily	primarili	N	O
in	IN	in	in	in	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
642	CD	642	642	642	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
follow	SYM	follow	follow	follow	N	O
-	:	-	-	-	N	O
up	IN	up	up	up	N	O
studies	NNS	studies	study	studi	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
with	IN	with	with	with	N	O
RLS	NNP	rls	rls	rl	N	O
ranged	VBD	ranged	ranged	rang	N	O
from	IN	from	from	from	N	O
18	CD	18	18	18	N	O
to	TO	to	to	to	N	O
82	CD	82	82	82	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
60%	CD	60%	60%	60%	N	O
being	VBG	being	being	be	N	O
female	JJ	female	female	femal	N	O
and	CC	and	and	and	N	O
95%	CD	95%	95%	95%	N	O
being	VBG	being	being	be	N	O
Caucasian	JJ	caucasian	caucasian	caucasian	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
in	IN	in	in	in	N	O
doses	NNS	doses	dos	dose	N	O
ranging	VBG	ranging	ranging	rang	N	O
from	IN	from	from	from	N	O
600	CD	600	600	600	N	O
to	TO	to	to	to	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
400	CD	400	400	400	N	O
mg	NN	mg	mg	mg	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
in	IN	in	in	in	N	O
515	CD	515	515	515	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
RLS	NNP	rls	rls	rl	N	O
in	IN	in	in	in	N	O
3	CD	3	3	3	N	O
double	JJ	double	double	doubl	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
12	CD	12	12	12	N	O
week	NN	week	week	week	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
600	CD	600	600	600	N	O
-	:	-	-	-	N	O
mg	NN	mg	mg	mg	N	O
dose	NN	dose	dose	dose	N	O
was	VBD	was	wa	wa	N	O
studied	VBN	studied	studied	studi	N	O
in	IN	in	in	in	N	O
2	CD	2	2	2	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
3	CD	3	3	3	N	O
studies	NNS	studies	study	studi	N	O
.	.	.	.	.	N	O

Eleven	RB	eleven	eleven	eleven	N	O
out	IN	out	out	out	N	O
of	IN	of	of	of	N	O
163	CD	163	163	163	N	O
(	(	(	(	(	N	O
7%	CD	7%	7%	7%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
600	CD	600	600	600	N	O
mg	NNS	mg	mg	mg	N	O
of	IN	of	of	of	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
discontinued	VBD	discontinued	discontinued	discontinu	N	O
treatment	NN	treatment	treatment	treatment	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
10	CD	10	10	10	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
245	CD	245	245	245	N	O
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
commonly	RB	commonly	commonly	commonli	N	O
observed	JJ	observed	observed	observ	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
2	CD	2	2	2	N	O
times	NNS	times	time	time	N	O
the	DT	the	the	the	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
trials	NNS	trials	trial	trial	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
600	CD	600	600	600	N	O
mg	NN	mg	mg	mg	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
were	VBD	were	were	were	N	O
somnolence	JJ	somnolence	somnolence	somnol	Y	B-AdverseReaction
sedation	NN	sedation	sedation	sedat	Y	B-AdverseReaction
and	CC	and	and	and	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
(	(	(	(	(	N	O
see	VB	see	see	see	N	O
Table	NNP	table	table	tabl	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
lists	NNS	lists	list	list	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
emergent	JJ	emergent	emergent	emerg	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
RLS	NNP	rls	rls	rl	N	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
and	CC	and	and	and	N	O
numerically	RB	numerically	numerically	numer	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
.	.	.	.	.	N	O

Incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
12	CD	12	12	12	N	O
Week	JJ	week	week	week	N	O
RLS	NNP	rls	rls	rl	N	O
Studies	NNPS	studies	study	studi	N	O
Reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
Treated	VBN	treated	treated	treat	N	O
With	IN	with	with	with	N	O
600	CD	600	600	600	N	O
or	CC	or	or	or	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
200	CD	200	200	200	N	O
mg	NN	mg	mg	mg	N	O
of	IN	of	of	of	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
and	CC	and	and	and	N	O
Numerically	RB	numerically	numerically	numer	N	O
Greater	NNP	greater	greater	greater	N	O
Than	NNP	than	than	than	N	O
Placebo	NNP	placebo	placebo	placebo	N	O

Body	NN	body	body	bodi	N	O
System	NNP	system	system	system	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
a	DT	a	a	a	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
245	CD	245	245	245	N	O
)	)	)	)	)	N	O
HORIZANT600	NNP	horizant600	horizant600	horizant600	N	O
mg	FW	mg	mg	mg	N	O
day	NN	day	day	day	N	O
b	NN	b	b	b	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
163	CD	163	163	163	N	O
)	)	)	)	)	N	O
HORIZANT1	NNP	horizant1	horizant1	horizant1	N	O
,	,	,	,	,	N	O
200	CD	200	200	200	N	O
mg	NN	mg	mg	mg	N	O
day	NN	day	day	day	N	O
c	VB	c	c	c	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
269	CD	269	269	269	N	O
)	)	)	)	)	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O

Somnolence	NNP	somnolence	somnolence	somnol	Y	B-AdverseReaction
sedation	NN	sedation	sedation	sedat	Y	B-AdverseReaction
6	CD	6	6	6	N	O
20	CD	20	20	20	N	O
27	CD	27	27	27	N	O

Dizziness	NNP	dizziness	dizziness	dizzi	Y	B-AdverseReaction
4	CD	4	4	4	N	O
13	CD	13	13	13	N	O
22	CD	22	22	22	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
11	CD	11	11	11	N	O
12	CD	12	12	12	N	O
15	CD	15	15	15	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
5	CD	5	5	5	N	O
6	CD	6	6	6	N	O
7	CD	7	7	7	N	O

Dry	NNP	dry	dry	dri	N	B-AdverseReaction
mouth	VBD	mouth	mouth	mouth	N	I-AdverseReaction
2	CD	2	2	2	N	O
3	CD	3	3	3	N	O
4	CD	4	4	4	N	O

Flatulence	NN	flatulence	flatulence	flatul	Y	B-AdverseReaction
1	CD	1	1	1	N	O
3	CD	3	3	3	N	O
2	CD	2	2	2	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O

Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
4	CD	4	4	4	N	O
6	CD	6	6	6	N	O
7	CD	7	7	7	N	O

Irritability	NNP	irritability	irritability	irrit	Y	B-AdverseReaction
1	CD	1	1	1	N	O
4	CD	4	4	4	N	O
4	CD	4	4	4	N	O

Feeling	VBG	feeling	feeling	feel	N	B-AdverseReaction
drunk	NN	drunk	drunk	drunk	N	I-AdverseReaction
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O
3	CD	3	3	3	N	O

Feeling	VBG	feeling	feeling	feel	N	B-AdverseReaction
abnormal	JJ	abnormal	abnormal	abnorm	N	I-AdverseReaction
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O
3	CD	3	3	3	N	O

Peripheral	NNP	peripheral	peripheral	peripher	N	B-AdverseReaction
edema	VBD	edema	edema	edema	Y	I-AdverseReaction
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O
3	CD	3	3	3	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
nutritional	JJ	nutritional	nutritional	nutrit	N	O
disorders	NNS	disorders	disorder	disord	N	O

Weight	NNP	weight	weight	weight	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
2	CD	2	2	2	N	O
2	CD	2	2	2	N	O
3	CD	3	3	3	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
appetite	RB	appetite	appetite	appetit	N	I-AdverseReaction
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
2	CD	2	2	2	N	O

Ear	NN	ear	ear	ear	N	O
and	CC	and	and	and	N	O
labyrinth	NN	labyrinth	labyrinth	labyrinth	N	O
disorders	NNS	disorders	disorder	disord	N	O

Vertigo	NNP	vertigo	vertigo	vertigo	Y	B-AdverseReaction
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O
3	CD	3	3	3	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
disorders	NNS	disorders	disorder	disord	N	O

Depression	NNP	depression	depression	depress	Y	B-AdverseReaction
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O
3	CD	3	3	3	N	O

Libido	NNP	libido	libido	libido	N	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O

a	DT	a	a	a	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
was	VBD	was	wa	wa	N	O
a	DT	a	a	a	N	O
treatment	NN	treatment	treatment	treatment	N	O
arm	NN	arm	arm	arm	N	O
in	IN	in	in	in	N	O
each	DT	each	each	each	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
3	CD	3	3	3	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
12	CD	12	12	12	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

b	VB	b	b	b	N	O
The	DT	the	the	the	N	O
600	CD	600	600	600	N	O
-	:	-	-	-	N	O
mg	NN	mg	mg	mg	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
was	VBD	was	wa	wa	N	O
a	DT	a	a	a	N	O
treatment	NN	treatment	treatment	treatment	N	O
arm	NN	arm	arm	arm	N	O
in	IN	in	in	in	N	O
2	CD	2	2	2	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
3	CD	3	3	3	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
12	CD	12	12	12	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

c	VB	c	c	c	N	O
The	DT	the	the	the	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
200	CD	200	200	200	N	O
-	:	-	-	-	N	O
mg	NN	mg	mg	mg	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
was	VBD	was	wa	wa	N	O
a	DT	a	a	a	N	O
treatment	NN	treatment	treatment	treatment	N	O
arm	NN	arm	arm	arm	N	O
in	IN	in	in	in	N	O
each	DT	each	each	each	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
3	CD	3	3	3	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
12	CD	12	12	12	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Adverse	NN	adverse	adverse	advers	N	O

reactions	NNS	reactions	reaction	reaction	N	O

reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
three	CD	three	three	three	N	O
12	CD	12	12	12	N	O
week	NN	week	week	week	N	O
studies	NNS	studies	study	studi	N	O
in	IN	in	in	in	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
600	CD	600	600	600	N	O
mg	NNS	mg	mg	mg	N	O
of	IN	of	of	of	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
and	CC	and	and	and	N	O
numerically	RB	numerically	numerically	numer	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
were	VBD	were	were	were	N	O
balance	NN	balance	balance	balanc	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
blurred	VBN	blurred	blurred	blur	N	B-AdverseReaction
vision	NN	vision	vision	vision	N	I-AdverseReaction
,	,	,	,	,	N	O
disorientation	NN	disorientation	disorientation	disorient	Y	B-AdverseReaction
,	,	,	,	,	N	O
feeling	VBG	feeling	feeling	feel	N	B-AdverseReaction
drunk	NN	drunk	drunk	drunk	N	I-AdverseReaction
,	,	,	,	,	N	O
lethargy	NN	lethargy	lethargy	lethargi	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
vertigo	NN	vertigo	vertigo	vertigo	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
dose	JJ	dose	dose	dose	N	O
-	:	-	-	-	N	O
related	VBN	related	related	relat	N	O
:	:	:	:	:	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
sedation	NN	sedation	sedation	sedat	Y	B-AdverseReaction
,	,	,	,	,	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
feeling	VBG	feeling	feeling	feel	N	B-AdverseReaction
drunk	NN	drunk	drunk	drunk	N	I-AdverseReaction
,	,	,	,	,	N	O
libido	NN	libido	libido	libido	N	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
,	,	,	,	,	N	O
depression	NN	depression	depression	depress	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
vertigo	NN	vertigo	vertigo	vertigo	Y	B-AdverseReaction
.	.	.	.	.	N	O

Postherpetic	JJ	postherpetic	postherpetic	postherpet	N	O
Neuralgia	NNP	neuralgia	neuralgia	neuralgia	Y	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
in	IN	in	in	in	N	O
417	CD	417	417	417	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
PHN	NNP	phn	phn	phn	N	O
included	VBD	included	included	includ	N	O
207	CD	207	207	207	N	O
patients	NNS	patients	patient	patient	N	O
exposed	VBN	exposed	exposed	expos	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
3	CD	3	3	3	N	O
months	NNS	months	month	month	N	O
.	.	.	.	.	N	O

Overall	JJ	overall	overall	overal	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
PHN	NNP	phn	phn	phn	N	O
studies	NNS	studies	study	studi	N	O
ranged	VBD	ranged	ranged	rang	N	O
from	IN	from	from	from	N	O
61	CD	61	61	61	N	O
to	TO	to	to	to	N	O
64	CD	64	64	64	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
across	IN	across	across	across	N	O
dose	JJ	dose	dose	dose	N	O
groups	NNS	groups	group	group	N	O
;	:	;	;	;	N	O
the	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
male	JJ	male	male	male	N	O
(	(	(	(	(	N	O
45%	CD	45%	45%	45%	N	O
to	TO	to	to	to	N	O
61%	CD	61%	61%	61%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Caucasian	NNP	caucasian	caucasian	caucasian	N	O
(	(	(	(	(	N	O
80%	CD	80%	80%	80%	N	O
to	TO	to	to	to	N	O
98%	CD	98%	98%	98%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
in	IN	in	in	in	N	O
doses	NNS	doses	dos	dose	N	O
ranging	VBG	ranging	ranging	rang	N	O
from	IN	from	from	from	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
200	CD	200	200	200	N	O
to	TO	to	to	to	N	O
3	CD	3	3	3	N	O
,	,	,	,	,	N	O
600	CD	600	600	600	N	O
mg	NN	mg	mg	mg	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
in	IN	in	in	in	N	O
417	CD	417	417	417	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
PHN	NNP	phn	phn	phn	N	O
in	IN	in	in	in	N	O
3	CD	3	3	3	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
principal	JJ	principal	principal	princip	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
study	NN	study	study	studi	N	O
evaluating	VBG	evaluating	evaluating	evalu	N	O
the	DT	the	the	the	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
and	CC	and	and	and	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
management	NN	management	management	manag	N	O
of	IN	of	of	of	N	O
PHN	NNP	phn	phn	phn	N	O
was	VBD	was	wa	wa	N	O
a	DT	a	a	a	N	O
12	CD	12	12	12	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
multicenter	NN	multicenter	multicenter	multicent	N	O
study	NN	study	study	studi	N	O
comparing	VBG	comparing	comparing	compar	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
200	CD	200	200	200	N	O
mg	NN	mg	mg	mg	N	O
day	NN	day	day	day	N	O
,	,	,	,	,	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
400	CD	400	400	400	N	O
mg	NN	mg	mg	mg	N	O
day	NN	day	day	day	N	O
and	CC	and	and	and	N	O
3	CD	3	3	3	N	O
,	,	,	,	,	N	O
600	CD	600	600	600	N	O
mg	NN	mg	mg	mg	N	O
day	NN	day	day	day	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Six	CD	six	six	six	N	O
out	IN	out	out	out	N	O
of	IN	of	of	of	N	O
107	CD	107	107	107	N	O
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
200	CD	200	200	200	N	O
mg	NN	mg	mg	mg	N	O
of	IN	of	of	of	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
discontinued	VBD	discontinued	discontinued	discontinu	N	O
treatment	NN	treatment	treatment	treatment	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
12	CD	12	12	12	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
95	CD	95	95	95	N	O
(	(	(	(	(	N	O
13%	CD	13%	13%	13%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
commonly	RB	commonly	commonly	commonli	N	O
observed	JJ	observed	observed	observ	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
and	CC	and	and	and	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
trial	NN	trial	trial	trial	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
200	CD	200	200	200	N	O
mg	NN	mg	mg	mg	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
were	VBD	were	were	were	N	O
dizziness	JJ	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
(	(	(	(	(	N	O
see	VB	see	see	see	N	O
Table	NNP	table	table	tabl	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
5	CD	5	5	5	N	O
lists	NNS	lists	list	list	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
emergent	JJ	emergent	emergent	emerg	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
PHN	NNP	phn	phn	phn	N	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
200	CD	200	200	200	N	O
mg	NN	mg	mg	mg	N	O
day	NN	day	day	day	N	O
and	CC	and	and	and	N	O
numerically	RB	numerically	numerically	numer	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
5	CD	5	5	5	N	O
.	.	.	.	.	N	O

Incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
in	IN	in	in	in	N	O
At	IN	at	at	at	N	O
Least	NNP	least	least	least	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
Treated	VBN	treated	treated	treat	N	O
With	IN	with	with	with	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
200	CD	200	200	200	N	O
mg	JJ	mg	mg	mg	N	O
day	NN	day	day	day	N	O
of	IN	of	of	of	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
and	CC	and	and	and	N	O
Numerically	RB	numerically	numerically	numer	N	O
Greater	NNP	greater	greater	greater	N	O
Than	NNP	than	than	than	N	O
the	DT	the	the	the	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
Rate	NNP	rate	rate	rate	N	O
)	)	)	)	)	N	O
Reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
All	DT	all	all	all	N	O
Patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
12	CD	12	12	12	N	O
-	:	-	-	-	N	O
Week	NN	week	week	week	N	O
PHN	NNP	phn	phn	phn	N	O
Study	NNP	study	study	studi	N	O

Body	NN	body	body	bodi	N	O
System	NNP	system	system	system	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
95	CD	95	95	95	N	O
)	)	)	)	)	N	O
HORIZANT1	NNP	horizant1	horizant1	horizant1	N	O
,	,	,	,	,	N	O
200	CD	200	200	200	N	O
mg	NN	mg	mg	mg	N	O
day	NN	day	day	day	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
107	CD	107	107	107	N	O
)	)	)	)	)	N	O
HORIZANT2	NNP	horizant2	horizant2	horizant2	N	O
,	,	,	,	,	N	O
400	CD	400	400	400	N	O
mg	NN	mg	mg	mg	N	O
day	NN	day	day	day	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
82	CD	82	82	82	N	O
)	)	)	)	)	N	O
HORIZANT3	NNP	horizant3	horizant3	horizant3	N	O
,	,	,	,	,	N	O
600	CD	600	600	600	N	O
mg	NN	mg	mg	mg	N	O
day	NN	day	day	day	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
87	CD	87	87	87	N	O
)	)	)	)	)	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
System	NN	system	system	system	N	O

Dizziness	NNP	dizziness	dizziness	dizzi	Y	B-AdverseReaction
15	CD	15	15	15	N	O
17	CD	17	17	17	N	O
26	CD	26	26	26	N	O
30	CD	30	30	30	N	O

Somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
8	CD	8	8	8	N	O
10	CD	10	10	10	N	O
11	CD	11	11	11	N	O
14	CD	14	14	14	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
9	CD	9	9	9	N	O
10	CD	10	10	10	N	O
10	CD	10	10	10	N	O
7	CD	7	7	7	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
5	CD	5	5	5	N	O
8	CD	8	8	8	N	O
4	CD	4	4	4	N	O
9	CD	9	9	9	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O

Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
Asthenia	NNP	asthenia	asthenia	asthenia	Y	B-AdverseReaction
1	CD	1	1	1	N	O
6	CD	6	6	6	N	O
4	CD	4	4	4	N	O
10	CD	10	10	10	N	O

Peripheral	NNP	peripheral	peripheral	peripher	N	B-AdverseReaction
edema	VBD	edema	edema	edema	Y	I-AdverseReaction
0	CD	0	0	0	N	O
6	CD	6	6	6	N	O
7	CD	7	7	7	N	O
6	CD	6	6	6	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
disorders	NNS	disorders	disorder	disord	N	O

Insomnia	NNP	insomnia	insomnia	insomnia	Y	B-AdverseReaction
2	CD	2	2	2	N	O
3	CD	3	3	3	N	O
5	CD	5	5	5	N	O
7	CD	7	7	7	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
nutritional	JJ	nutritional	nutritional	nutrit	N	O
disorders	NNS	disorders	disorder	disord	N	O

Weight	NNP	weight	weight	weight	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
1	CD	1	1	1	N	O
3	CD	3	3	3	N	O
5	CD	5	5	5	N	O
5	CD	5	5	5	N	O

Eye	NN	eye	eye	eye	N	O
disorders	NNS	disorders	disorder	disord	N	O

Blurred	NNP	blurred	blurred	blur	N	B-AdverseReaction
vision	NN	vision	vision	vision	N	I-AdverseReaction
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
5	CD	5	5	5	N	O
2	CD	2	2	2	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
also	RB	also	also	also	N	O
reported	VBN	reported	reported	report	N	O
as	IN	as	a	as	N	O
2%	CD	2%	2%	2%	N	O
at	IN	at	at	at	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
400	CD	400	400	400	N	O
mg	NN	mg	mg	mg	N	O
day	NN	day	day	day	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
3	CD	3	3	3	N	O
,	,	,	,	,	N	O
600	CD	600	600	600	N	O
mg	NN	mg	mg	mg	N	O
day	NN	day	day	day	N	O
and	CC	and	and	and	N	O
appeared	VBD	appeared	appeared	appear	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
dose	JJ	dose	dose	dose	N	O
-	:	-	-	-	N	O
related	VBN	related	related	relat	N	O
but	CC	but	but	but	N	O
were	VBD	were	were	were	N	O
2%	CD	2%	2%	2%	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
200	CD	200	200	200	N	O
mg	JJ	mg	mg	mg	N	O
day	NN	day	day	day	N	O
:	:	:	:	:	N	O
balance	NN	balance	balance	balanc	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
confusional	JJ	confusional	confusional	confusion	N	B-AdverseReaction
state	NN	state	state	state	N	I-AdverseReaction
,	,	,	,	,	N	O
depression	NN	depression	depression	depress	Y	B-AdverseReaction
,	,	,	,	,	N	O
dry	JJ	dry	dry	dri	N	B-AdverseReaction
mouth	NN	mouth	mouth	mouth	N	I-AdverseReaction
,	,	,	,	,	N	O
flatulence	NN	flatulence	flatulence	flatul	Y	B-AdverseReaction
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
appetite	RB	appetite	appetite	appetit	N	I-AdverseReaction
,	,	,	,	,	N	O
irritability	NN	irritability	irritability	irrit	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
vertigo	NN	vertigo	vertigo	vertigo	Y	B-AdverseReaction
.	.	.	.	.	N	O

Dizziness	NNP	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
insomnia	RB	insomnia	insomnia	insomnia	Y	B-AdverseReaction
appeared	VBD	appeared	appeared	appear	N	O
to	TO	to	to	to	N	O
show	VB	show	show	show	N	O
a	DT	a	a	a	N	O
dose	JJ	dose	dose	dose	N	O
relationship	NN	relationship	relationship	relationship	N	O
.	.	.	.	.	N	O

6.2	CD	6.2	6.2	6.2	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Events	NNS	events	event	event	N	O
Associated	VBN	associated	associated	associ	N	O
With	IN	with	with	with	N	O
Gabapentin	NNP	gabapentin	gabapentin	gabapentin	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
gabapentin	NN	gabapentin	gabapentin	gabapentin	N	O
,	,	,	,	,	N	O
either	RB	either	either	either	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
or	CC	or	or	or	N	O
postmarketing	NN	postmarketing	postmarketing	postmarket	N	O
:	:	:	:	:	N	O
breast	NN	breast	breast	breast	N	B-AdverseReaction
enlargement	NN	enlargement	enlargement	enlarg	N	I-AdverseReaction
,	,	,	,	,	N	O
gynecomastia	NN	gynecomastia	gynecomastia	gynecomastia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
elevated	VBD	elevated	elevated	elev	N	B-AdverseReaction
creatine	JJ	creatine	creatine	creatin	Y	I-AdverseReaction
kinase	NN	kinase	kinase	kinas	N	I-AdverseReaction
.	.	.	.	.	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Driving	JJ	driving	driving	drive	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
:	:	:	:	:	N	O
Warn	JJ	warn	warn	warn	N	O
patients	NNS	patients	patient	patient	N	O
not	RB	not	not	not	N	O
to	TO	to	to	to	N	O
drive	VB	drive	drive	drive	N	O
until	IN	until	until	until	N	O
they	PRP	they	they	they	N	O
have	VBP	have	have	have	N	O
gained	VBN	gained	gained	gain	N	O
sufficient	JJ	sufficient	sufficient	suffici	N	O
experience	NN	experience	experience	experi	N	O
with	IN	with	with	with	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
to	TO	to	to	to	N	O
assess	VB	assess	ass	assess	N	O
whether	IN	whether	whether	whether	N	O
it	PRP	it	it	it	N	O
will	MD	will	will	will	N	O
impair	VB	impair	impair	impair	N	O
their	PRP$	their	their	their	N	O
ability	NN	ability	ability	abil	N	O
to	TO	to	to	to	N	O
drive	VB	drive	drive	drive	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

Somnolence	NNP	somnolence	somnolence	somnol	Y	B-AdverseReaction
sedation	NN	sedation	sedation	sedat	Y	B-AdverseReaction
and	CC	and	and	and	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
:	:	:	:	:	N	O
May	NNP	may	may	may	N	B-Factor
impair	VB	impair	impair	impair	N	B-AdverseReaction
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
's	POS	's	's	's	N	O
ability	NN	ability	ability	abil	N	I-AdverseReaction
to	TO	to	to	to	N	I-AdverseReaction
operate	VB	operate	operate	oper	N	I-AdverseReaction
complex	JJ	complex	complex	complex	N	I-AdverseReaction
machinery	NN	machinery	machinery	machineri	N	I-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

HORIZANT	NNP	horizant	horizant	horiz	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
interchangeable	JJ	interchangeable	interchangeable	interchang	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
gabapentin	NN	gabapentin	gabapentin	gabapentin	N	O
products	NNS	products	product	product	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

Suicidal	NNP	suicidal	suicidal	suicid	N	B-AdverseReaction
thoughts	NNS	thoughts	thought	thought	N	I-AdverseReaction
or	CC	or	or	or	N	O
behaviors	NNS	behaviors	behavior	behavior	N	I-AdverseReaction
:	:	:	:	:	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
prodrug	NN	prodrug	prodrug	prodrug	N	O
of	IN	of	of	of	N	O
gabapentin	NN	gabapentin	gabapentin	gabapentin	N	O
,	,	,	,	,	N	O
an	DT	an	an	an	N	O
antiepileptic	JJ	antiepileptic	antiepileptic	antiepilept	N	O
drug	NN	drug	drug	drug	N	O
(	(	(	(	(	N	O
AED	NNP	aed	aed	a	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

AEDs	NNP	aeds	aeds	a	N	B-DrugClass
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	B-AdverseReaction
thoughts	NNS	thoughts	thought	thought	N	I-AdverseReaction
or	CC	or	or	or	N	O
behaviors	NNS	behaviors	behavior	behavior	N	I-AdverseReaction
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	O
thoughts	NNS	thoughts	thought	thought	N	O
or	CC	or	or	or	N	O
behaviors	NNS	behaviors	behavior	behavior	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Effects	NNS	effects	effect	effect	N	O

on	IN	on	on	on	N	O
Driving	VBG	driving	driving	drive	N	O

HORIZANT	NNP	horizant	horizant	horiz	N	O
may	MD	may	may	may	N	B-Factor
cause	VB	cause	cause	caus	N	O
significant	JJ	significant	significant	signific	N	B-Severity
driving	VBG	driving	driving	drive	N	B-AdverseReaction
impairment	JJ	impairment	impairment	impair	N	I-AdverseReaction
[	NN	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.3	CD	14.3	14.3	14.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
driving	VBG	driving	driving	drive	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
after	IN	after	after	after	N	O
starting	VBG	starting	starting	start	N	O
therapy	NN	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
drive	VB	drive	drive	drive	N	O
until	IN	until	until	until	N	O
they	PRP	they	they	they	N	O
have	VBP	have	have	have	N	O
gained	VBN	gained	gained	gain	N	O
sufficient	JJ	sufficient	sufficient	suffici	N	O
experience	NN	experience	experience	experi	N	O
to	TO	to	to	to	N	O
assess	VB	assess	ass	assess	N	O
whether	IN	whether	whether	whether	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
impairs	VBP	impairs	impairs	impair	N	O
their	PRP$	their	their	their	N	O
ability	NN	ability	ability	abil	N	O
to	TO	to	to	to	N	O
drive	VB	drive	drive	drive	N	O
.	.	.	.	.	N	O

However	RB	however	however	howev	N	O
,	,	,	,	,	N	O
prescribers	NNS	prescribers	prescribers	prescrib	N	O
and	CC	and	and	and	N	O
patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
aware	JJ	aware	aware	awar	N	O
that	IN	that	that	that	N	O
patients	NNS	patients	patient	patient	N	O
ability	NN	ability	ability	abil	N	O
to	TO	to	to	to	N	O
assess	VB	assess	ass	assess	N	O
their	PRP$	their	their	their	N	O
own	JJ	own	own	own	N	O
driving	NN	driving	driving	drive	N	O
competence	NN	competence	competence	compet	N	O
,	,	,	,	,	N	O
as	RB	as	a	as	N	O
well	RB	well	well	well	N	O
as	IN	as	a	as	N	O
their	PRP$	their	their	their	N	O
ability	NN	ability	ability	abil	N	O
to	TO	to	to	to	N	O
assess	VB	assess	ass	assess	N	O
the	DT	the	the	the	N	O
degree	NN	degree	degree	degre	N	O
of	IN	of	of	of	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	O
caused	VBN	caused	caused	caus	N	O
by	IN	by	by	by	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
,	,	,	,	,	N	O
can	MD	can	can	can	N	O
be	VB	be	be	be	N	O
imperfect	JJ	imperfect	imperfect	imperfect	N	O
.	.	.	.	.	N	O

Whether	IN	whether	whether	whether	N	O
the	DT	the	the	the	N	O
impairment	NN	impairment	impairment	impair	N	O
is	VBZ	is	is	is	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
somnolence	VB	somnolence	somnolence	somnol	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VB	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
effects	NNS	effects	effect	effect	N	O
of	IN	of	of	of	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Somnolence	NNP	somnolence	somnolence	somnol	Y	O
Sedation	NNP	sedation	sedation	sedat	Y	O
and	CC	and	and	and	N	O
Dizziness	NNP	dizziness	dizziness	dizzi	Y	O

HORIZANT	NNP	horizant	horizant	horiz	N	O
causes	VBZ	causes	cause	caus	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
sedation	NN	sedation	sedation	sedat	Y	B-AdverseReaction
and	CC	and	and	and	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
(	(	(	(	(	N	O
see	VB	see	see	see	N	O
Tables	NNP	tables	table	tabl	N	O
4	CD	4	4	4	N	O
and	CC	and	and	and	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
advised	VBN	advised	advised	advis	N	O
not	RB	not	not	not	N	O
to	TO	to	to	to	N	O
drive	VB	drive	drive	drive	N	O
a	DT	a	a	a	N	O
car	NN	car	car	car	N	O
or	CC	or	or	or	N	O
operate	VB	operate	operate	oper	N	O
other	JJ	other	other	other	N	O
complex	JJ	complex	complex	complex	N	O
machinery	NN	machinery	machinery	machineri	N	O
until	IN	until	until	until	N	O
they	PRP	they	they	they	N	O
have	VBP	have	have	have	N	O
gained	VBN	gained	gained	gain	N	O
sufficient	JJ	sufficient	sufficient	suffici	N	O
experience	NN	experience	experience	experi	N	O
on	IN	on	on	on	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
to	TO	to	to	to	N	O
assess	VB	assess	ass	assess	N	O
whether	IN	whether	whether	whether	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
impairs	VBP	impairs	impairs	impair	N	O
their	PRP$	their	their	their	N	O
ability	NN	ability	ability	abil	N	O
to	TO	to	to	to	N	O
perform	VB	perform	perform	perform	N	O
these	DT	these	these	these	N	O
tasks	NNS	tasks	task	task	N	O
.	.	.	.	.	N	O

During	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
RLS	NNP	rls	rls	rl	N	O
,	,	,	,	,	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
sedation	NN	sedation	sedation	sedat	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
20%	CD	20%	20%	20%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
600	CD	600	600	600	N	O
mg	NNS	mg	mg	mg	N	O
of	IN	of	of	of	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
per	IN	per	per	per	N	O
day	NN	day	day	day	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
6%	CD	6%	6%	6%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
those	DT	those	those	those	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
who	WP	who	who	who	N	O
reported	VBD	reported	reported	report	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
persisted	VBD	persisted	persisted	persist	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
in	IN	in	in	in	N	O
about	RB	about	about	about	N	O
30%	CD	30%	30%	30%	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
remaining	VBG	remaining	remaining	remain	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
resolved	VBD	resolved	resolved	resolv	N	O
within	IN	within	within	within	N	O
3	CD	3	3	3	N	O
to	TO	to	to	to	N	O
4	CD	4	4	4	N	O
weeks	NNS	weeks	week	week	N	O
.	.	.	.	.	N	O

Dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
13%	CD	13%	13%	13%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
600	CD	600	600	600	N	O
mg	NN	mg	mg	mg	N	O
of	IN	of	of	of	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
per	IN	per	per	per	N	O
day	NN	day	day	day	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
4%	CD	4%	4%	4%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
those	DT	those	those	those	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
who	WP	who	who	who	N	O
reported	VBD	reported	reported	report	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
persisted	VBD	persisted	persisted	persist	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
in	IN	in	in	in	N	O
about	RB	about	about	about	N	O
20%	CD	20%	20%	20%	N	O
.	.	.	.	.	N	O

Somnolence	NNP	somnolence	somnolence	somnol	Y	B-AdverseReaction
sedation	NN	sedation	sedation	sedat	Y	B-AdverseReaction
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
withdrawal	VB	withdrawal	withdrawal	withdraw	N	O
in	IN	in	in	in	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
600	CD	600	600	600	N	O
mg	NN	mg	mg	mg	N	O
of	IN	of	of	of	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
per	IN	per	per	per	N	O
day	NN	day	day	day	N	O
.	.	.	.	.	N	O

Dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
withdrawal	VB	withdrawal	withdrawal	withdraw	N	O
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
600	CD	600	600	600	N	O
mg	NN	mg	mg	mg	N	O
of	IN	of	of	of	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
per	IN	per	per	per	N	O
day	NN	day	day	day	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
was	VBD	was	wa	wa	N	O
greater	JJR	greater	greater	greater	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
200	CD	200	200	200	N	O
mg	NNS	mg	mg	mg	N	O
per	IN	per	per	per	N	O
day	NN	day	day	day	N	O
.	.	.	.	.	N	O

During	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
12	CD	12	12	12	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
controlled	VBD	controlled	controlled	control	N	O
study	NN	study	study	studi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
PHN	NNP	phn	phn	phn	N	O
,	,	,	,	,	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
200	CD	200	200	200	N	O
mg	NN	mg	mg	mg	N	O
of	IN	of	of	of	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
per	IN	per	per	per	N	O
day	NN	day	day	day	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
8%	CD	8%	8%	8%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
6%	CD	6%	6%	6%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
200	CD	200	200	200	N	O
mg	NN	mg	mg	mg	N	O
of	IN	of	of	of	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
per	IN	per	per	per	N	O
day	NN	day	day	day	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
those	DT	those	those	those	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
200	CD	200	200	200	N	O
mg	NN	mg	mg	mg	N	O
of	IN	of	of	of	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
per	IN	per	per	per	N	O
day	NN	day	day	day	N	O
who	WP	who	who	who	N	O
reported	VBD	reported	reported	report	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
persisted	VBD	persisted	persisted	persist	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
in	IN	in	in	in	N	O
about	RB	about	about	about	N	O
27%	CD	27%	27%	27%	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
remaining	VBG	remaining	remaining	remain	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
resolved	VBD	resolved	resolved	resolv	N	O
within	IN	within	within	within	N	O
4	CD	4	4	4	N	O
to	TO	to	to	to	N	O
5	CD	5	5	5	N	O
weeks	NNS	weeks	week	week	N	O
.	.	.	.	.	N	O

Dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
17%	CD	17%	17%	17%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
200	CD	200	200	200	N	O
mg	NN	mg	mg	mg	N	O
of	IN	of	of	of	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
per	IN	per	per	per	N	O
day	NN	day	day	day	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
15%	CD	15%	15%	15%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
those	DT	those	those	those	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
200	CD	200	200	200	N	O
mg	NN	mg	mg	mg	N	O
of	IN	of	of	of	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
per	IN	per	per	per	N	O
day	NN	day	day	day	N	O
who	WP	who	who	who	N	O
reported	VBD	reported	reported	report	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
persisted	VBD	persisted	persisted	persist	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
in	IN	in	in	in	N	O
about	RB	about	about	about	N	O
6%	CD	6%	6%	6%	N	O
.	.	.	.	.	N	O

Somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
withdrawal	VB	withdrawal	withdrawal	withdraw	N	O
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
200	CD	200	200	200	N	O
mg	NN	mg	mg	mg	N	O
of	IN	of	of	of	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
per	IN	per	per	per	N	O
day	NN	day	day	day	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
withdrawal	VB	withdrawal	withdrawal	withdraw	N	O
in	IN	in	in	in	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
200	CD	200	200	200	N	O
mg	NN	mg	mg	mg	N	O
of	IN	of	of	of	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
per	IN	per	per	per	N	O
day	NN	day	day	day	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
3%	CD	3%	3%	3%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Lack	NNP	lack	lack	lack	N	O
of	IN	of	of	of	N	O
Interchangeability	NNP	interchangeability	interchangeability	interchang	N	O
With	IN	with	with	with	N	O
Gabapentin	NNP	gabapentin	gabapentin	gabapentin	N	O

HORIZANT	NNP	horizant	horizant	horiz	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
interchangeable	JJ	interchangeable	interchangeable	interchang	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
gabapentin	NN	gabapentin	gabapentin	gabapentin	N	O
products	NNS	products	product	product	N	O
because	IN	because	because	becaus	N	O
of	IN	of	of	of	N	O
differing	VBG	differing	differing	differ	N	O
pharmacokinetic	JJ	pharmacokinetic	pharmacokinetic	pharmacokinet	N	O
profiles	NNS	profiles	profile	profil	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
same	JJ	same	same	same	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
results	NNS	results	result	result	N	O
in	IN	in	in	in	N	O
different	JJ	different	different	differ	N	O
plasma	JJ	plasma	plasma	plasma	N	O
concentrations	NNS	concentrations	concentration	concentr	N	O
of	IN	of	of	of	N	O
gabapentin	NN	gabapentin	gabapentin	gabapentin	N	O
relative	NN	relative	relative	rel	N	O
to	TO	to	to	to	N	O
other	JJ	other	other	other	N	O
gabapentin	NN	gabapentin	gabapentin	gabapentin	N	O
products	NNS	products	product	product	N	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
See	NNP	see	see	see	N	O
Clinical	NNP	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.3	CD	12.3	12.3	12.3	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O
]	NN	]	]	]	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
and	CC	and	and	and	N	O
effectiveness	NN	effectiveness	effectiveness	effect	N	O
of	IN	of	of	of	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
epilepsy	NNS	epilepsy	epilepsy	epilepsi	Y	O
have	VBP	have	have	have	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
studied	VBN	studied	studied	studi	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Suicidal	NNP	suicidal	suicidal	suicid	N	O
Behavior	NNP	behavior	behavior	behavior	N	O
and	CC	and	and	and	N	O
Ideation	NNP	ideation	ideation	ideat	N	O

HORIZANT	NNP	horizant	horizant	horiz	N	O
(	(	(	(	(	N	O
gabapentin	JJ	gabapentin	gabapentin	gabapentin	N	O
enacarbil	NN	enacarbil	enacarbil	enacarbil	N	O
)	)	)	)	)	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
prodrug	NN	prodrug	prodrug	prodrug	N	O
of	IN	of	of	of	N	O
gabapentin	NN	gabapentin	gabapentin	gabapentin	N	O
,	,	,	,	,	N	O
an	DT	an	an	an	N	O
antiepileptic	JJ	antiepileptic	antiepileptic	antiepilept	N	O
drug	NN	drug	drug	drug	N	O
(	(	(	(	(	N	O
AED	NNP	aed	aed	a	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

AEDs	NNP	aeds	aeds	a	N	B-DrugClass
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	B-AdverseReaction
thoughts	NNS	thoughts	thought	thought	N	I-AdverseReaction
or	CC	or	or	or	N	O
behavior	NN	behavior	behavior	behavior	N	I-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
these	DT	these	these	these	N	O
drugs	NNS	drugs	drug	drug	N	O
for	IN	for	for	for	N	O
any	DT	any	any	ani	N	O
indication	NN	indication	indication	indic	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
prodrug	NN	prodrug	prodrug	prodrug	N	O
of	IN	of	of	of	N	O
gabapentin	NN	gabapentin	gabapentin	gabapentin	N	O
,	,	,	,	,	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
also	RB	also	also	also	N	O
increases	VBZ	increases	increase	increas	N	O
this	DT	this	this	thi	N	O
risk	NN	risk	risk	risk	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
any	DT	any	any	ani	N	O
AED	NNP	aed	aed	a	N	O
for	IN	for	for	for	N	O
any	DT	any	any	ani	N	O
indication	NN	indication	indication	indic	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
emergence	NN	emergence	emergence	emerg	N	O
or	CC	or	or	or	N	O
worsening	NN	worsening	worsening	worsen	N	O
of	IN	of	of	of	N	O
depression	NN	depression	depression	depress	Y	O
,	,	,	,	,	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	O
thoughts	NNS	thoughts	thought	thought	N	O
or	CC	or	or	or	N	O
behavior	NN	behavior	behavior	behavior	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
any	DT	any	any	ani	N	O
unusual	JJ	unusual	unusual	unusu	N	O
changes	NNS	changes	change	chang	N	O
in	IN	in	in	in	N	O
mood	NN	mood	mood	mood	N	O
or	CC	or	or	or	N	O
behavior	NN	behavior	behavior	behavior	N	O
.	.	.	.	.	N	O

Pooled	JJ	pooled	pooled	pool	N	O
analyses	NNS	analyses	analysis	analys	N	O
of	IN	of	of	of	N	O
199	CD	199	199	199	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
(	(	(	(	(	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
and	CC	and	and	and	N	O
adjunctive	JJ	adjunctive	adjunctive	adjunct	N	O
therapy	NN	therapy	therapy	therapi	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
11	CD	11	11	11	N	O
different	JJ	different	different	differ	N	O
AEDs	NNP	aeds	aeds	a	N	O
showed	VBD	showed	showed	show	N	O
that	IN	that	that	that	N	O
patients	NNS	patients	patient	patient	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
1	CD	1	1	1	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
AEDs	NNP	aeds	aeds	a	N	B-DrugClass
had	VBD	had	had	had	N	O
approximately	RB	approximately	approximately	approxim	N	O
twice	RB	twice	twice	twice	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
[	NNP	[	[	[	N	O
adjusted	VBD	adjusted	adjusted	adjust	N	O
relative	JJ	relative	relative	rel	N	O
risk	NN	risk	risk	risk	N	O
1.8	CD	1.8	1.8	1.8	N	O
,	,	,	,	,	N	O
95%	CD	95%	95%	95%	N	O
confidence	NN	confidence	confidence	confid	N	O
interval	NN	interval	interval	interv	N	O
(	(	(	(	(	N	O
CI	NNP	ci	ci	ci	N	O
)	)	)	)	)	N	O
:	:	:	:	:	N	O
1.2	CD	1.2	1.2	1.2	N	O
,	,	,	,	,	N	O
2.7	CD	2.7	2.7	2.7	N	O
]	NN	]	]	]	N	O
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	B-AdverseReaction
thinking	NN	thinking	thinking	think	N	I-AdverseReaction
or	CC	or	or	or	N	O
behavior	NN	behavior	behavior	behavior	N	I-AdverseReaction
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
patients	NNS	patients	patient	patient	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
these	DT	these	these	these	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
median	JJ	median	median	median	N	O
treatment	NN	treatment	treatment	treatment	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
12	CD	12	12	12	N	O
weeks	NNS	weeks	week	week	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
estimated	VBN	estimated	estimated	estim	N	O
incidence	NN	incidence	incidence	incid	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	B-AdverseReaction
behavior	NN	behavior	behavior	behavior	N	I-AdverseReaction
or	CC	or	or	or	N	O
ideation	NN	ideation	ideation	ideat	N	I-AdverseReaction
among	IN	among	among	among	N	O
27	CD	27	27	27	N	O
,	,	,	,	,	N	O
863	CD	863	863	863	N	O
AED	NNP	aed	aed	a	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
was	VBD	was	wa	wa	N	O
0.43%	CD	0.43%	0.43%	0.43%	N	O
,	,	,	,	,	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
0.24%	CD	0.24%	0.24%	0.24%	N	O
among	IN	among	among	among	N	O
16	CD	16	16	16	N	O
,	,	,	,	,	N	O
029	CD	029	029	029	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
representing	VBG	representing	representing	repres	N	O
an	DT	an	an	an	N	O
increase	NN	increase	increase	increas	N	O
of	IN	of	of	of	N	O
approximately	RB	approximately	approximately	approxim	N	O
1	CD	1	1	1	N	O
case	NN	case	case	case	N	O
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	B-AdverseReaction
thinking	NN	thinking	thinking	think	N	I-AdverseReaction
or	CC	or	or	or	N	O
behavior	NN	behavior	behavior	behavior	N	I-AdverseReaction
for	IN	for	for	for	N	O
every	DT	every	every	everi	N	O
530	CD	530	530	530	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
4	CD	4	4	4	N	O
suicides	NNS	suicides	suicide	suicid	N	B-AdverseReaction
in	IN	in	in	in	N	O
drug	NN	drug	drug	drug	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
trials	NNS	trials	trial	trial	N	O
and	CC	and	and	and	N	O
none	NN	none	none	none	N	O
in	IN	in	in	in	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
the	DT	the	the	the	N	O
number	NN	number	number	number	N	B-Factor
is	VBZ	is	is	is	N	I-Factor
too	RB	too	too	too	N	I-Factor
small	JJ	small	small	small	N	I-Factor
to	TO	to	to	to	N	O
allow	VB	allow	allow	allow	N	O
any	DT	any	any	ani	N	O
conclusion	NN	conclusion	conclusion	conclus	N	O
about	IN	about	about	about	N	O
drug	NN	drug	drug	drug	N	O
effect	NN	effect	effect	effect	N	O
on	IN	on	on	on	N	O
suicide	NN	suicide	suicide	suicid	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	B-AdverseReaction
thoughts	NNS	thoughts	thought	thought	N	I-AdverseReaction
or	CC	or	or	or	N	O
behavior	NN	behavior	behavior	behavior	N	I-AdverseReaction
with	IN	with	with	with	N	O
AEDs	NNP	aeds	aeds	a	N	B-DrugClass
was	VBD	was	wa	wa	N	O
observed	VBN	observed	observed	observ	N	O
as	RB	as	a	as	N	O
early	JJ	early	early	earli	N	O
as	IN	as	a	as	N	O
1	CD	1	1	1	N	O
week	NN	week	week	week	N	O
after	IN	after	after	after	N	O
starting	VBG	starting	starting	start	N	O
drug	NN	drug	drug	drug	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
AEDs	NNP	aeds	aeds	a	N	O
and	CC	and	and	and	N	O
persisted	VBN	persisted	persisted	persist	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
assessed	VBN	assessed	assessed	assess	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
most	JJS	most	most	most	N	O
trials	NNS	trials	trial	trial	N	O
included	VBD	included	included	includ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
analysis	NN	analysis	analysis	analysi	N	O
did	VBD	did	did	did	N	O
not	RB	not	not	not	N	O
extend	VB	extend	extend	extend	N	O
beyond	IN	beyond	beyond	beyond	N	O
24	CD	24	24	24	N	O
weeks	NNS	weeks	week	week	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	O
thoughts	NNS	thoughts	thought	thought	N	O
or	CC	or	or	or	N	O
behavior	JJ	behavior	behavior	behavior	N	O
beyond	IN	beyond	beyond	beyond	N	O
24	CD	24	24	24	N	O
weeks	NNS	weeks	week	week	N	O
could	MD	could	could	could	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
assessed	VBN	assessed	assessed	assess	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	B-AdverseReaction
thoughts	NNS	thoughts	thought	thought	N	I-AdverseReaction
or	CC	or	or	or	N	O
behavior	NN	behavior	behavior	behavior	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
generally	RB	generally	generally	gener	N	O
consistent	JJ	consistent	consistent	consist	N	O
among	IN	among	among	among	N	O
drugs	NNS	drugs	drug	drug	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
analyzed	VBD	analyzed	analyzed	analyz	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
finding	NN	finding	finding	find	N	O
of	IN	of	of	of	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
with	IN	with	with	with	N	O
AEDs	NNP	aeds	aeds	a	N	O
of	IN	of	of	of	N	O
varying	VBG	varying	varying	vari	N	O
mechanisms	NNS	mechanisms	mechanism	mechan	N	O
of	IN	of	of	of	N	O
action	NN	action	action	action	N	O
and	CC	and	and	and	N	O
across	IN	across	across	across	N	O
a	DT	a	a	a	N	O
range	NN	range	range	rang	N	O
of	IN	of	of	of	N	O
indications	NNS	indications	indication	indic	N	O
suggests	VBZ	suggests	suggests	suggest	N	O
that	IN	that	that	that	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
applies	NNS	applies	applies	appli	N	O
to	TO	to	to	to	N	O
all	DT	all	all	all	N	O
AEDs	NNP	aeds	aeds	a	N	O
used	VBN	used	used	use	N	O
for	IN	for	for	for	N	O
any	DT	any	any	ani	N	O
indication	NN	indication	indication	indic	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
did	VBD	did	did	did	N	O
not	RB	not	not	not	N	O
vary	JJ	vary	vary	vari	N	O
substantially	RB	substantially	substantially	substanti	N	O
by	IN	by	by	by	N	O
age	NN	age	age	age	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
to	TO	to	to	to	N	O
100	CD	100	100	100	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
analyzed	VBD	analyzed	analyzed	analyz	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
shows	NNS	shows	show	show	N	O
absolute	NN	absolute	absolute	absolut	N	O
and	CC	and	and	and	N	O
relative	JJ	relative	relative	rel	N	O
risk	NN	risk	risk	risk	N	O
by	IN	by	by	by	N	O
indication	NN	indication	indication	indic	N	O
for	IN	for	for	for	N	O
all	DT	all	all	all	N	O
evaluated	JJ	evaluated	evaluated	evalu	N	O
AEDs	NNP	aeds	aeds	a	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
.	.	.	.	.	N	O

Risk	NN	risk	risk	risk	N	O
by	IN	by	by	by	N	O
Indication	NNP	indication	indication	indic	N	O
for	IN	for	for	for	N	O
Antiepileptic	NNP	antiepileptic	antiepileptic	antiepilept	N	O
Drugs	NNP	drugs	drug	drug	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Pooled	NNP	pooled	pooled	pool	N	O
Analysis	NN	analysis	analysis	analysi	N	O

Indication	NN	indication	indication	indic	N	O
PlaceboPatients	NNS	placebopatients	placebopatients	placebopati	N	O
WithEvents	NNP	withevents	withevents	withev	N	O
Per1	NNP	per1	per1	per1	N	O
,	,	,	,	,	N	O
000	CD	000	000	000	N	O
Patients	NNS	patients	patient	patient	N	O
Drug	NNP	drug	drug	drug	N	O
PatientsWith	NNP	patientswith	patientswith	patientswith	N	O
Events	NNP	events	event	event	N	O
Per1	NNP	per1	per1	per1	N	O
,	,	,	,	,	N	O
000	CD	000	000	000	N	O
Patients	NNS	patients	patient	patient	N	O
Relative	JJ	relative	relative	rel	N	O
Risk	NN	risk	risk	risk	N	O
:	:	:	:	:	N	O
Incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
Eventsin	NNP	eventsin	eventsin	eventsin	N	O
DrugPatients	NNP	drugpatients	drugpatients	drugpati	N	O
Incidencein	NNP	incidencein	incidencein	incidencein	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
Patients	NNP	patients	patient	patient	N	O
Risk	NNP	risk	risk	risk	N	O
Difference	NNP	difference	difference	differ	N	O
:	:	:	:	:	N	O
Additional	JJ	additional	additional	addit	N	O
DrugPatients	NNS	drugpatients	drugpatients	drugpati	N	O
WithEvents	NNS	withevents	withevents	withev	N	O
Per	IN	per	per	per	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
000	CD	000	000	000	N	O
Patients	NNS	patients	patient	patient	N	O

Epilepsy	NNP	epilepsy	epilepsy	epilepsi	Y	O
1.0	CD	1.0	1.0	1.0	N	O
3.4	CD	3.4	3.4	3.4	N	O
3.5	CD	3.5	3.5	3.5	N	O
2.4	CD	2.4	2.4	2.4	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
5.7	CD	5.7	5.7	5.7	N	O
8.5	CD	8.5	8.5	8.5	N	O
1.5	CD	1.5	1.5	1.5	N	O
2.9	CD	2.9	2.9	2.9	N	O

Other	JJ	other	other	other	N	O
1.0	CD	1.0	1.0	1.0	N	O
1.8	CD	1.8	1.8	1.8	N	O
1.9	CD	1.9	1.9	1.9	N	O
0.9	CD	0.9	0.9	0.9	N	O

Total	JJ	total	total	total	N	O
2.4	CD	2.4	2.4	2.4	N	O
4.3	CD	4.3	4.3	4.3	N	O
1.8	CD	1.8	1.8	1.8	N	O
1.9	CD	1.9	1.9	1.9	N	O

The	DT	the	the	the	N	O
relative	JJ	relative	relative	rel	N	O
risk	NN	risk	risk	risk	N	B-Factor
for	IN	for	for	for	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	B-AdverseReaction
thoughts	NNS	thoughts	thought	thought	N	I-AdverseReaction
or	CC	or	or	or	N	O
behavior	NN	behavior	behavior	behavior	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
higher	RBR	higher	higher	higher	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
for	IN	for	for	for	N	O
epilepsy	NN	epilepsy	epilepsy	epilepsi	Y	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
for	IN	for	for	for	N	O
psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
the	DT	the	the	the	N	O
absolute	NN	absolute	absolute	absolut	N	O
risk	NN	risk	risk	risk	N	O
differences	NNS	differences	difference	differ	N	O
were	VBD	were	were	were	N	O
similar	JJ	similar	similar	similar	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
epilepsy	NN	epilepsy	epilepsy	epilepsi	Y	O
and	CC	and	and	and	N	O
psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
indications	NNS	indications	indication	indic	N	O
.	.	.	.	.	N	O

Anyone	NN	anyone	anyone	anyon	N	O

considering	VBG	considering	considering	consid	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
must	MD	must	must	must	N	O
balance	VB	balance	balance	balanc	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	O
thoughts	NNS	thoughts	thought	thought	N	O
or	CC	or	or	or	N	O
behavior	NN	behavior	behavior	behavior	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
untreated	JJ	untreated	untreated	untreat	N	O
illness	NN	illness	illness	ill	N	O
.	.	.	.	.	N	O

Epilepsy	NNP	epilepsy	epilepsy	epilepsi	Y	O
and	CC	and	and	and	N	O
many	JJ	many	many	mani	N	O
other	JJ	other	other	other	N	O
illnesses	NNS	illnesses	illness	ill	N	O
for	IN	for	for	for	N	O
which	WDT	which	which	which	N	O
AEDs	NNP	aeds	aeds	a	N	O
are	VBP	are	are	are	N	O
prescribed	VBN	prescribed	prescribed	prescrib	N	O
are	VBP	are	are	are	N	O
themselves	PRP	themselves	themselves	themselv	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
morbidity	NN	morbidity	morbidity	morbid	N	O
and	CC	and	and	and	N	O
mortality	NN	mortality	mortality	mortal	N	O
and	CC	and	and	and	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	O
thoughts	NNS	thoughts	thought	thought	N	O
and	CC	and	and	and	N	O
behavior	NN	behavior	behavior	behavior	N	O
.	.	.	.	.	N	O

Should	MD	should	should	should	N	O
suicidal	VB	suicidal	suicidal	suicid	N	O
thoughts	NNS	thoughts	thought	thought	N	O
and	CC	and	and	and	N	O
behavior	JJ	behavior	behavior	behavior	N	O
emerge	NN	emerge	emerge	emerg	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
prescriber	NN	prescriber	prescriber	prescrib	N	O
needs	VBZ	needs	need	need	N	O
to	TO	to	to	to	N	O
consider	VB	consider	consider	consid	N	O
whether	IN	whether	whether	whether	N	O
the	DT	the	the	the	N	O
emergence	NN	emergence	emergence	emerg	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
in	IN	in	in	in	N	O
any	DT	any	any	ani	N	O
given	VBN	given	given	given	N	O
patient	NN	patient	patient	patient	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
illness	NN	illness	illness	ill	N	O
being	VBG	being	being	be	N	O
treated	VBN	treated	treated	treat	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
their	PRP$	their	their	their	N	O
caregivers	NNS	caregivers	caregiver	caregiv	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
families	NNS	families	family	famili	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
informed	VBN	informed	informed	inform	N	O
that	IN	that	that	that	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
increases	VBZ	increases	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	O
thoughts	NNS	thoughts	thought	thought	N	O
and	CC	and	and	and	N	O
behavior	NN	behavior	behavior	behavior	N	O
and	CC	and	and	and	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
advised	VBN	advised	advised	advis	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
need	NN	need	need	need	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
alert	JJ	alert	alert	alert	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
emergence	NN	emergence	emergence	emerg	N	O
or	CC	or	or	or	N	O
worsening	NN	worsening	worsening	worsen	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
depression	NN	depression	depression	depress	Y	O
,	,	,	,	,	N	O
any	DT	any	any	ani	N	O
unusual	JJ	unusual	unusual	unusu	N	O
changes	NNS	changes	change	chang	N	O
in	IN	in	in	in	N	O
mood	NN	mood	mood	mood	N	O
or	CC	or	or	or	N	O
behavior	NN	behavior	behavior	behavior	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
the	DT	the	the	the	N	O
emergence	NN	emergence	emergence	emerg	N	O
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	O
thoughts	NNS	thoughts	thought	thought	N	O
,	,	,	,	,	N	O
behavior	NN	behavior	behavior	behavior	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
thoughts	NNS	thoughts	thought	thought	N	O
about	IN	about	about	about	N	O
self	PRP	self	self	self	N	O
-	:	-	-	-	N	O
harm	NN	harm	harm	harm	N	O
.	.	.	.	.	N	O

Behaviors	NNS	behaviors	behavior	behavior	N	O
of	IN	of	of	of	N	O
concern	NN	concern	concern	concern	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
reported	VBN	reported	reported	report	N	O
immediately	RB	immediately	immediately	immedi	N	O
to	TO	to	to	to	N	O
healthcare	VB	healthcare	healthcare	healthcar	N	O
providers	NNS	providers	provider	provid	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Drug	NNP	drug	drug	drug	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
With	IN	with	with	with	N	O
Eosinophilia	NNP	eosinophilia	eosinophilia	eosinophilia	Y	O
and	CC	and	and	and	N	O
Systemic	NNP	systemic	systemic	system	N	O
Symptoms	NNP	symptoms	symptom	symptom	N	O
(	(	(	(	(	N	O
DRESS	NNP	dress	dress	dress	N	O
)	)	)	)	)	N	O
Multiorgan	NNP	multiorgan	multiorgan	multiorgan	N	O
Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	O

Drug	NNP	drug	drug	drug	N	B-AdverseReaction
Reaction	NNP	reaction	reaction	reaction	N	I-AdverseReaction
with	IN	with	with	with	N	I-AdverseReaction
Eosinophilia	NNP	eosinophilia	eosinophilia	eosinophilia	Y	I-AdverseReaction
and	CC	and	and	and	N	I-AdverseReaction
Systemic	NNP	systemic	systemic	system	N	I-AdverseReaction
Symptoms	NNP	symptoms	symptom	symptom	N	I-AdverseReaction
(	(	(	(	(	N	O
DRESS	NNP	dress	dress	dress	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
also	RB	also	also	also	N	O
known	VBN	known	known	known	N	O
as	IN	as	a	as	N	O
multiorgan	JJ	multiorgan	multiorgan	multiorgan	N	B-AdverseReaction
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	I-AdverseReaction
,	,	,	,	,	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
antiepileptic	JJ	antiepileptic	antiepileptic	antiepilept	N	B-DrugClass
drugs	NNS	drugs	drug	drug	N	I-DrugClass
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
gabapentin	NN	gabapentin	gabapentin	gabapentin	N	O
.	.	.	.	.	N	O

HORIZANT	NNP	horizant	horizant	horiz	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
prodrug	NN	prodrug	prodrug	prodrug	N	O
of	IN	of	of	of	N	O
gabapentin	NN	gabapentin	gabapentin	gabapentin	N	O
.	.	.	.	.	N	O

Some	DT	some	some	some	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
or	CC	or	or	or	N	O
life	NN	life	life	life	N	O
-	:	-	-	-	N	O
threatening	NN	threatening	threatening	threaten	N	O
.	.	.	.	.	N	O

DRESS	NNP	dress	dress	dress	N	B-AdverseReaction
typically	RB	typically	typically	typic	N	O
,	,	,	,	,	N	O
although	IN	although	although	although	N	O
not	RB	not	not	not	N	O
exclusively	RB	exclusively	exclusively	exclus	N	O
,	,	,	,	,	N	O
presents	NNS	presents	present	present	N	O
with	IN	with	with	with	N	O
fever	NN	fever	fever	fever	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
lymphadenopathy	JJ	lymphadenopathy	lymphadenopathy	lymphadenopathi	Y	B-AdverseReaction
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
association	NN	association	association	associ	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
organ	JJ	organ	organ	organ	N	O
system	NN	system	system	system	N	O
involvement	NN	involvement	involvement	involv	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	B-AdverseReaction
,	,	,	,	,	N	O
nephritis	NN	nephritis	nephritis	nephriti	Y	B-AdverseReaction
,	,	,	,	,	N	O
hematological	JJ	hematological	hematological	hematolog	N	B-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
,	,	,	,	,	N	O
myocarditis	NN	myocarditis	myocarditis	myocard	Y	B-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
myositis	NN	myositis	myositis	myositi	Y	B-AdverseReaction
sometimes	RB	sometimes	sometimes	sometim	N	O
resembling	VBG	resembling	resembling	resembl	N	O
an	DT	an	an	an	N	O
acute	JJ	acute	acute	acut	N	O
viral	JJ	viral	viral	viral	N	O
infection	NN	infection	infection	infect	Y	O
.	.	.	.	.	N	O

Eosinophilia	NNP	eosinophilia	eosinophilia	eosinophilia	Y	B-AdverseReaction
is	VBZ	is	is	is	N	O
often	RB	often	often	often	N	O
present	JJ	present	present	present	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
this	DT	this	this	thi	N	O
disorder	NN	disorder	disorder	disord	N	O
is	VBZ	is	is	is	N	O
variable	JJ	variable	variable	variabl	N	O
in	IN	in	in	in	N	O
its	PRP$	its	it	it	N	O
expression	NN	expression	expression	express	N	O
,	,	,	,	,	N	O
other	JJ	other	other	other	N	O
organ	JJ	organ	organ	organ	N	O
systems	NNS	systems	system	system	N	O
not	RB	not	not	not	N	O
noted	VBN	noted	noted	note	N	O
here	RB	here	here	here	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
involved	VBN	involved	involved	involv	N	O
.	.	.	.	.	N	O

It	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
important	JJ	important	important	import	N	O
to	TO	to	to	to	N	O
note	VB	note	note	note	N	O
that	IN	that	that	that	N	O
early	JJ	early	early	earli	N	O
manifestations	NNS	manifestations	manifestation	manifest	N	O
of	IN	of	of	of	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
fever	NN	fever	fever	fever	Y	B-AdverseReaction
or	CC	or	or	or	N	O
lymphadenopathy	JJ	lymphadenopathy	lymphadenopathy	lymphadenopathi	Y	B-AdverseReaction
,	,	,	,	,	N	O
may	MD	may	may	may	N	B-Factor
be	VB	be	be	be	N	O
present	JJ	present	present	present	N	O
even	RB	even	even	even	N	O
though	IN	though	though	though	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	B-Negation
evident	JJ	evident	evident	evid	N	I-Negation
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
such	JJ	such	such	such	N	O
signs	NNS	signs	sign	sign	N	O
or	CC	or	or	or	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
are	VBP	are	are	are	N	O
present	JJ	present	present	present	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
immediately	RB	immediately	immediately	immedi	N	O
.	.	.	.	.	N	O

HORIZANT	NNP	horizant	horizant	horiz	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
if	IN	if	if	if	N	O
an	DT	an	an	an	N	O
alternative	JJ	alternative	alternative	altern	N	O
etiology	NN	etiology	etiology	etiolog	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
signs	NNS	signs	sign	sign	N	O
or	CC	or	or	or	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
cannot	VBP	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
established	VBN	established	established	establish	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O

When	WRB	when	when	when	N	O
discontinuing	VBG	discontinuing	discontinuing	discontinu	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
RLS	NNP	rls	rls	rl	N	O
receiving	VBG	receiving	receiving	receiv	N	O
600	CD	600	600	600	N	O
mg	NN	mg	mg	mg	N	O
or	CC	or	or	or	N	O
less	JJR	less	le	less	N	O
once	RB	once	once	onc	N	O
daily	JJ	daily	daily	daili	N	O
can	MD	can	can	can	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
the	DT	the	the	the	N	O
drug	NN	drug	drug	drug	N	O
without	IN	without	without	without	N	O
tapering	VBG	tapering	tapering	taper	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
the	DT	the	the	the	N	O
recommended	VBN	recommended	recommended	recommend	N	O
dose	NN	dose	dose	dose	N	O
is	VBZ	is	is	is	N	O
exceeded	VBN	exceeded	exceeded	exceed	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
dose	NN	dose	dose	dose	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
reduced	VBN	reduced	reduced	reduc	N	O
to	TO	to	to	to	N	O
600	CD	600	600	600	N	O
mg	NNS	mg	mg	mg	N	O
daily	RB	daily	daily	daili	N	O
for	IN	for	for	for	N	O
1	CD	1	1	1	N	O
week	NN	week	week	week	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
to	TO	to	to	to	N	O
minimize	VB	minimize	minimize	minim	N	O
the	DT	the	the	the	N	O
potential	NN	potential	potential	potenti	N	O
of	IN	of	of	of	N	O
withdrawal	NN	withdrawal	withdrawal	withdraw	N	O
seizure	NN	seizure	seizure	seizur	Y	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
PHN	NNP	phn	phn	phn	N	O
receiving	VBG	receiving	receiving	receiv	N	O
HORIZANT	NNP	horizant	horizant	horiz	N	O
twice	JJ	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
dose	NN	dose	dose	dose	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
reduced	VBN	reduced	reduced	reduc	N	O
to	TO	to	to	to	N	O
once	RB	once	once	onc	N	O
daily	JJ	daily	daily	daili	N	O
for	IN	for	for	for	N	O
1	CD	1	1	1	N	O
week	NN	week	week	week	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
to	TO	to	to	to	N	O
minimize	VB	minimize	minimize	minim	N	O
the	DT	the	the	the	N	O
potential	NN	potential	potential	potenti	N	O
of	IN	of	of	of	N	O
withdrawal	NN	withdrawal	withdrawal	withdraw	N	O
seizure	NN	seizure	seizure	seizur	Y	O
,	,	,	,	,	N	O
see	VBP	see	see	see	N	O
Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
[	NN	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Tumorigenic	NNP	tumorigenic	tumorigenic	tumorigen	N	O
Potential	NNP	potential	potential	potenti	N	O

In	IN	in	in	in	N	O
an	DT	an	an	an	N	O
oral	JJ	oral	oral	oral	N	O
carcinogenicity	NN	carcinogenicity	carcinogenicity	carcinogen	Y	O
study	NN	study	study	studi	N	O
,	,	,	,	,	N	O
gabapentin	JJ	gabapentin	gabapentin	gabapentin	N	O
enacarbil	NN	enacarbil	enacarbil	enacarbil	N	O
increased	VBD	increased	increased	increas	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
pancreatic	JJ	pancreatic	pancreatic	pancreat	N	B-AdverseReaction
acinar	NN	acinar	acinar	acinar	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
adenoma	NN	adenoma	adenoma	adenoma	Y	I-AdverseReaction
and	CC	and	and	and	N	O
carcinoma	NN	carcinoma	carcinoma	carcinoma	Y	I-AdverseReaction
in	IN	in	in	in	N	O
male	NN	male	male	male	N	O
and	CC	and	and	and	N	O
female	JJ	female	female	femal	N	O
rats	NNS	rats	rat	rat	N	B-Animal
[	VBP	[	[	[	N	O
see	VB	see	see	see	N	O
Nonclinical	JJ	nonclinical	nonclinical	nonclin	N	O
Toxicology	NNP	toxicology	toxicology	toxicolog	N	O
(	(	(	(	(	N	O
13.1	CD	13.1	13.1	13.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
significance	NN	significance	significance	signific	N	O
of	IN	of	of	of	N	O
this	DT	this	this	thi	N	O
finding	NN	finding	finding	find	N	O
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
of	IN	of	of	of	N	O
gabapentin	NN	gabapentin	gabapentin	gabapentin	N	O
as	IN	as	a	as	N	O
adjunctive	JJ	adjunctive	adjunctive	adjunct	N	O
therapy	NN	therapy	therapy	therapi	N	O
in	IN	in	in	in	N	O
epilepsy	NN	epilepsy	epilepsy	epilepsi	Y	O
comprising	VBG	comprising	comprising	compris	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
085	CD	085	085	085	N	O
patient	JJ	patient	patient	patient	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
exposure	NN	exposure	exposure	exposur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
12	CD	12	12	12	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
,	,	,	,	,	N	O
new	JJ	new	new	new	N	O
tumors	NNS	tumors	tumor	tumor	N	B-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
10	CD	10	10	10	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
breast	NN	breast	breast	breast	N	I-AdverseReaction
,	,	,	,	,	N	O
3	CD	3	3	3	N	O
brain	NN	brain	brain	brain	N	I-AdverseReaction
,	,	,	,	,	N	O
2	CD	2	2	2	N	O
lung	NN	lung	lung	lung	N	I-AdverseReaction
,	,	,	,	,	N	O
1	CD	1	1	1	N	O
adrenal	JJ	adrenal	adrenal	adren	N	I-AdverseReaction
,	,	,	,	,	N	O
1	CD	1	1	1	N	O
non	SYM	non	non	non	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Hodgkin	NNP	hodgkin	hodgkin	hodgkin	N	I-AdverseReaction
's	POS	's	's	's	N	I-AdverseReaction
lymphoma	NN	lymphoma	lymphoma	lymphoma	Y	I-AdverseReaction
,	,	,	,	,	N	O
1	CD	1	1	1	N	O
endometrial	JJ	endometrial	endometrial	endometri	N	B-AdverseReaction
carcinoma	NN	carcinoma	carcinoma	carcinoma	Y	I-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
situ	NN	situ	situ	situ	N	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
preexisting	VBG	preexisting	preexisting	preexist	N	O
tumors	NNS	tumors	tumor	tumor	N	B-AdverseReaction
worsened	VBD	worsened	worsened	worsen	N	I-AdverseReaction
in	IN	in	in	in	N	O
11	CD	11	11	11	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
9	CD	9	9	9	N	O
brain	NN	brain	brain	brain	N	I-AdverseReaction
,	,	,	,	,	N	O
1	CD	1	1	1	N	O
breast	NN	breast	breast	breast	N	I-AdverseReaction
,	,	,	,	,	N	O
1	CD	1	1	1	N	O
prostate	NN	prostate	prostate	prostat	N	I-AdverseReaction
)	)	)	)	)	N	O
during	IN	during	during	dure	N	O
or	CC	or	or	or	N	O
up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
2	CD	2	2	2	N	O
years	NNS	years	year	year	N	O
following	VBG	following	following	follow	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
gabapentin	NN	gabapentin	gabapentin	gabapentin	N	O
.	.	.	.	.	N	O

Without	IN	without	without	without	N	O
knowledge	NN	knowledge	knowledge	knowledg	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
background	NN	background	background	background	N	O
incidence	NN	incidence	incidence	incid	N	O
and	CC	and	and	and	N	O
recurrence	NN	recurrence	recurrence	recurr	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
similar	JJ	similar	similar	similar	N	O
population	NN	population	population	popul	N	O
not	RB	not	not	not	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
gabapentin	NN	gabapentin	gabapentin	gabapentin	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
impossible	JJ	impossible	impossible	imposs	N	O
to	TO	to	to	to	N	O
know	VB	know	know	know	N	O
whether	IN	whether	whether	whether	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
cohort	NN	cohort	cohort	cohort	N	O
is	VBZ	is	is	is	N	O
or	CC	or	or	or	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
affected	VBN	affected	affected	affect	N	O
by	IN	by	by	by	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

